FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054294216> ?p ?o ?g. }

• W2054294216 endingPage "887" @default.
• W2054294216 startingPage "882" @default.
• W2054294216 abstract "From 1986 to 1988, 54 consecutive previously untreated patients with acute non-lymphoblastic leukaemia (ANLL), median age 54 years, were treated for remission (CR) induction with vincristine and intravenous medium-dose cytarabine sequentially followed by daunomycin and infusion cytarabine. CR patients received intensive consolidation. Bone marrow blast kinetics was studied before therapy with in vivo bromodeoxyuridine and bivariate flow cytometry. CR rate was 70.2%, median CR was 13.2 months, responsive patient survival was 16.9 months and overall survival was 9.2 months. Besides lower median age, the 33 responsive patients also had shorter potential doubling time (Tpot) and greater cell production rate (PR) than the 14 unresponsive patients (mean values = 10.9 vs. 25.4 days, P less than 0.05, and 14.7 vs. 8.9 cells/100 cells/day, P less than 0.02, respectively), due to a higher mean labelling index (7.0 vs. 5.1%, P less than 0.05) and/or to a shorter mean DNA synthesis time (13.6 vs. 18.6 hours, P less than 0.05). Besides lower white blood cell count and bone marrow blast percentage, patients who experienced CR longer than 13.2 months had shorter Tpot (P less than 0.05) and a greater PR (P less than 0.02) than those who relapsed before this time. These data indicate that kinetic parameters have prognostic relevance in ANLL patients treated with sequential vincristine, cytarabine and daunomycin for inducing CR and with intensive consolidation after CR, a high proliferative activity being a favourable factor for both CR achievement and its duration." @default.
• W2054294216 created "2016-06-24" @default.
• W2054294216 creator A5021756912 @default.
• W2054294216 creator A5033157635 @default.
• W2054294216 creator A5033692691 @default.
• W2054294216 creator A5070474995 @default.
• W2054294216 creator A5073540236 @default.
• W2054294216 creator A5078654521 @default.
• W2054294216 creator A5089288192 @default.
• W2054294216 date "1991-07-01" @default.
• W2054294216 modified "2023-09-25" @default.
• W2054294216 title "Cell kinetics with in vivo bromodeoxyuridine and flow cytometry: Clinical significance in acute non-lymphoblastic leukaemia" @default.
• W2054294216 cites W1965786046 @default.
• W2054294216 cites W1969551117 @default.
• W2054294216 cites W1984770264 @default.
• W2054294216 cites W1988975665 @default.
• W2054294216 cites W2001158027 @default.
• W2054294216 cites W2007598743 @default.
• W2054294216 cites W2023023793 @default.
• W2054294216 cites W2039709980 @default.
• W2054294216 cites W2058067215 @default.
• W2054294216 cites W2061165669 @default.
• W2054294216 cites W2065008538 @default.
• W2054294216 cites W2067704139 @default.
• W2054294216 cites W2077209061 @default.
• W2054294216 cites W2095575443 @default.
• W2054294216 cites W2124884335 @default.
• W2054294216 cites W2159456776 @default.
• W2054294216 cites W2252759819 @default.
• W2054294216 cites W2289270302 @default.
• W2054294216 cites W2313825221 @default.
• W2054294216 cites W2440358028 @default.
• W2054294216 cites W46583824 @default.
• W2054294216 doi "https://doi.org/10.1016/0277-5379(91)90139-5" @default.
• W2054294216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1834121" @default.
• W2054294216 hasPublicationYear "1991" @default.
• W2054294216 type Work @default.
• W2054294216 sameAs 2054294216 @default.
• W2054294216 citedByCount "23" @default.
• W2054294216 countsByYear W20542942162021 @default.
• W2054294216 crossrefType "journal-article" @default.
• W2054294216 hasAuthorship W2054294216A5021756912 @default.
• W2054294216 hasAuthorship W2054294216A5033157635 @default.
• W2054294216 hasAuthorship W2054294216A5033692691 @default.
• W2054294216 hasAuthorship W2054294216A5070474995 @default.
• W2054294216 hasAuthorship W2054294216A5073540236 @default.
• W2054294216 hasAuthorship W2054294216A5078654521 @default.
• W2054294216 hasAuthorship W2054294216A5089288192 @default.
• W2054294216 hasConcept C126322002 @default.
• W2054294216 hasConcept C141071460 @default.
• W2054294216 hasConcept C150903083 @default.
• W2054294216 hasConcept C185592680 @default.
• W2054294216 hasConcept C202751555 @default.
• W2054294216 hasConcept C203014093 @default.
• W2054294216 hasConcept C204232928 @default.
• W2054294216 hasConcept C207001950 @default.
• W2054294216 hasConcept C2776694085 @default.
• W2054294216 hasConcept C2776755627 @default.
• W2054294216 hasConcept C2778041864 @default.
• W2054294216 hasConcept C2778260397 @default.
• W2054294216 hasConcept C2778461978 @default.
• W2054294216 hasConcept C2779429289 @default.
• W2054294216 hasConcept C2780007613 @default.
• W2054294216 hasConcept C2781107101 @default.
• W2054294216 hasConcept C2909962599 @default.
• W2054294216 hasConcept C48900799 @default.
• W2054294216 hasConcept C553184892 @default.
• W2054294216 hasConcept C55493867 @default.
• W2054294216 hasConcept C71924100 @default.
• W2054294216 hasConcept C86803240 @default.
• W2054294216 hasConcept C90924648 @default.
• W2054294216 hasConceptScore W2054294216C126322002 @default.
• W2054294216 hasConceptScore W2054294216C141071460 @default.
• W2054294216 hasConceptScore W2054294216C150903083 @default.
• W2054294216 hasConceptScore W2054294216C185592680 @default.
• W2054294216 hasConceptScore W2054294216C202751555 @default.
• W2054294216 hasConceptScore W2054294216C203014093 @default.
• W2054294216 hasConceptScore W2054294216C204232928 @default.
• W2054294216 hasConceptScore W2054294216C207001950 @default.
• W2054294216 hasConceptScore W2054294216C2776694085 @default.
• W2054294216 hasConceptScore W2054294216C2776755627 @default.
• W2054294216 hasConceptScore W2054294216C2778041864 @default.
• W2054294216 hasConceptScore W2054294216C2778260397 @default.
• W2054294216 hasConceptScore W2054294216C2778461978 @default.
• W2054294216 hasConceptScore W2054294216C2779429289 @default.
• W2054294216 hasConceptScore W2054294216C2780007613 @default.
• W2054294216 hasConceptScore W2054294216C2781107101 @default.
• W2054294216 hasConceptScore W2054294216C2909962599 @default.
• W2054294216 hasConceptScore W2054294216C48900799 @default.
• W2054294216 hasConceptScore W2054294216C553184892 @default.
• W2054294216 hasConceptScore W2054294216C55493867 @default.
• W2054294216 hasConceptScore W2054294216C71924100 @default.
• W2054294216 hasConceptScore W2054294216C86803240 @default.
• W2054294216 hasConceptScore W2054294216C90924648 @default.
• W2054294216 hasIssue "7" @default.
• W2054294216 hasLocation W20542942161 @default.
• W2054294216 hasLocation W20542942162 @default.
• W2054294216 hasOpenAccess W2054294216 @default.

• next